Logo image of ONC

BEONE MEDICINES LTD-ADR (ONC) Stock Fundamental Analysis

USA - NASDAQ:ONC - US07725L1026 - ADR

324.34 USD
-11.33 (-3.38%)
Last: 9/12/2025, 8:06:04 PM
324.1 USD
-0.24 (-0.07%)
After Hours: 9/12/2025, 8:06:04 PM
Fundamental Rating

5

Overall ONC gets a fundamental rating of 5 out of 10. We evaluated ONC against 541 industry peers in the Biotechnology industry. While ONC seems to be doing ok healthwise, there are quite some concerns on its profitability. ONC is evaluated to be cheap and growing strongly. This does not happen too often!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ONC had positive earnings in the past year.
ONC had a positive operating cash flow in the past year.
In the past 5 years ONC always reported negative net income.
In the past 5 years ONC always reported negative operating cash flow.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2B -4B -6B -8B -10B

1.2 Ratios

Looking at the Return On Assets, with a value of -3.68%, ONC belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
Looking at the Return On Equity, with a value of -6.15%, ONC belongs to the top of the industry, outperforming 89.28% of the companies in the same industry.
Industry RankSector Rank
ROA -3.68%
ROE -6.15%
ROIC N/A
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ONC has a better Gross Margin (85.37%) than 88.35% of its industry peers.
ONC's Gross Margin has been stable in the last couple of years.
ONC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

5

2. Health

2.1 Basic Checks

ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONC has more shares outstanding than it did 1 year ago.
ONC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ONC has a worse debt to assets ratio.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.2 Solvency

An Altman-Z score of 8.60 indicates that ONC is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.60, ONC belongs to the top of the industry, outperforming 82.62% of the companies in the same industry.
ONC has a debt to FCF ratio of 5.47. This is a neutral value as ONC would need 5.47 years to pay back of all of its debts.
ONC has a better Debt to FCF ratio (5.47) than 92.42% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that ONC is not too dependend on debt financing.
The Debt to Equity ratio of ONC (0.26) is worse than 69.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.47
Altman-Z 8.6
ROIC/WACCN/A
WACC4.85%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B

2.3 Liquidity

ONC has a Current Ratio of 1.94. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
ONC has a worse Current ratio (1.94) than 75.97% of its industry peers.
ONC has a Quick Ratio of 1.71. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
ONC's Quick ratio of 1.71 is on the low side compared to the rest of the industry. ONC is outperformed by 78.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.71
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

7

3. Growth

3.1 Past

ONC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 217.74%, which is quite impressive.
Looking at the last year, ONC shows a very strong growth in Revenue. The Revenue has grown by 47.67%.
Measured over the past years, ONC shows a very strong growth in Revenue. The Revenue has been growing by 55.91% on average per year.
EPS 1Y (TTM)217.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.68%
Revenue 1Y (TTM)47.67%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.76%

3.2 Future

ONC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 94.26% yearly.
Based on estimates for the next years, ONC will show a quite strong growth in Revenue. The Revenue will grow by 18.90% on average per year.
EPS Next Y121.46%
EPS Next 2Y65.45%
EPS Next 3Y48.32%
EPS Next 5Y94.26%
Revenue Next Year38.52%
Revenue Next 2Y29.46%
Revenue Next 3Y24%
Revenue Next 5Y18.9%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20B 40B 60B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 500 1K 1.5K 2K

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 5.67, the valuation of ONC can be described as very cheap.
Based on the Price/Earnings ratio, ONC is valued cheaply inside the industry as 97.78% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.30, ONC is valued rather cheaply.
A Price/Forward Earnings ratio of 65.96 indicates a quite expensive valuation of ONC.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ONC indicates a rather cheap valuation: ONC is cheaper than 88.54% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, ONC is valued quite expensively.
Industry RankSector Rank
PE 5.67
Fwd PE 65.96
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ONC is valued cheaply inside the industry as 91.50% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 204.38
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

ONC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ONC's earnings are expected to grow with 48.32% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y65.45%
EPS Next 3Y48.32%

More info and screens

0

5. Dividend

5.1 Amount

ONC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEONE MEDICINES LTD-ADR

NASDAQ:ONC (9/12/2025, 8:06:04 PM)

After market: 324.1 -0.24 (-0.07%)

324.34

-11.33 (-3.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/dmh
Earnings (Next)11-12 2025-11-12
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change40.4%
Market Cap38.56B
Analysts81.43
Price Target344.56 (6.23%)
Short Float %18.44%
Short Ratio4.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.51
Dividend Growth(5Y)N/A
DP-30.61%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2148.49%
Min EPS beat(2)1187.13%
Max EPS beat(2)3109.85%
EPS beat(4)3
Avg EPS beat(4)1518.68%
Min EPS beat(4)-22.81%
Max EPS beat(4)3109.85%
EPS beat(8)4
Avg EPS beat(8)536.4%
EPS beat(12)5
Avg EPS beat(12)344.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.52%
Min Revenue beat(2)-1.25%
Max Revenue beat(2)6.29%
Revenue beat(4)3
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-1.25%
Max Revenue beat(4)6.29%
Revenue beat(8)7
Avg Revenue beat(8)13.13%
Revenue beat(12)11
Avg Revenue beat(12)13.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.52%
PT rev (3m)26.5%
EPS NQ rev (1m)1155.65%
EPS NQ rev (3m)N/A
EPS NY rev (1m)135.1%
EPS NY rev (3m)135.01%
Revenue NQ rev (1m)9.7%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.08%
Revenue NY rev (3m)0.66%
Valuation
Industry RankSector Rank
PE 5.67
Fwd PE 65.96
P/S 8.39
P/FCF 204.38
P/OCF 79.05
P/B 10.23
P/tB 10.73
EV/EBITDA N/A
EPS(TTM)57.18
EY17.63%
EPS(NY)4.92
Fwd EY1.52%
FCF(TTM)1.59
FCFY0.49%
OCF(TTM)4.1
OCFY1.26%
SpS38.65
BVpS31.71
TBVpS30.24
PEG (NY)0.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.68%
ROE -6.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.37%
FCFM 4.11%
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score6
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.71
Altman-Z 8.6
F-Score6
WACC4.85%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)217.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.68%
EPS Next Y121.46%
EPS Next 2Y65.45%
EPS Next 3Y48.32%
EPS Next 5Y94.26%
Revenue 1Y (TTM)47.67%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.76%
Revenue Next Year38.52%
Revenue Next 2Y29.46%
Revenue Next 3Y24%
Revenue Next 5Y18.9%
EBIT growth 1Y89.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.94%
EBIT Next 3Y63.92%
EBIT Next 5Y55.19%
FCF growth 1Y110.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y136.32%
OCF growth 3YN/A
OCF growth 5YN/A